Year: 2023
Type: review
Abstract: Systemic treatment for advanced hepatocellular carcinoma (HCC) has been revolutionized over the last few years following the approval of immune checkpoint inhibitors (ICI). Despite the promising survival extension seen with ICI combination regimens, responses are not universally seen and the optimal partner for programmed cell death 1 pathway inhibitors remains to be identified. Even fewer encouraging results have been demonstrated with ICI used for monotherapy. Several mechanisms of resistance have been described so far, involving characteristics of cancer cells (intrinsic mechanisms) and of the surrounding tumor microenvironment (extrinsic mechanisms). Factors related to therapy may also contribute to the development of resistance. Increasing research efforts are being dedicated to the discovery of novel approaches and targets to overcome resistance, some of which may be introduced into clinic in the future. Herein we describe a selection of resistance mechanisms that have been involved in impairing response to ICI and propose potential therapeutic approaches to overcome resistance.
DOI: 10.2147/jhc.s291553
Authors: Giulia Francesca Manfredi, Ciro Celsa, Chloe John, Charlotte Jones, Nicole Acuti, Bernhard Scheiner, Claudia Angela Maria Fulgenzi, James Korolewicz, Matthias Pinter, Alessandra Gennari, Francesco Mauri, Mario Pirisi, Rosalba Minisini, Federica Vincenzi, Michela Burlone, Cristina Rigamonti, Matteo Donadon, Giuseppe Cabibbo, Antonio D'Alessio, David James Pinato
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,836
Awards: G1611021288, G2921181837
OpenAlex ID: W4388301636
